Documenting the natural history of patients with resected stage II adenocarcinoma of the colon after random assignment to adjuvant treatment with edrecolomab or observation: Results from CALGB 9581 Academic Article uri icon

Overview

MeSH Major

  • Adenocarcinoma
  • Antibodies, Monoclonal
  • Antineoplastic Agents
  • Colonic Neoplasms

abstract

  • Edrecolomab did not prolong survival. Consequently, this large study with a long duration of follow-up provided unique data concerning the natural history of resected stage II colon cancer. Prognostic factors identified in previous retrospective and pooled analyses were associated with survival outcomes in this stage II patient cohort. Results from ongoing molecular marker studies may enhance our ability to determine the risk profile of these patients.

publication date

  • August 10, 2011

Research

keywords

  • Academic Article

Identity

Language

  • eng

PubMed Central ID

  • PMC3157980

Digital Object Identifier (DOI)

  • 10.1200/JCO.2010.32.5357

PubMed ID

  • 21747085

Additional Document Info

start page

  • 3146

end page

  • 52

volume

  • 29

number

  • 23